Revolution Medicines, Inc.
RVMD
$149.94
$4.222.90%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 343.97M | 294.94M | 262.51M | 19.13M | 205.75M |
| Gross Profit | -343.97M | -294.94M | -262.51M | -19.13M | -205.75M |
| SG&A Expenses | 101.25M | 66.68M | 52.76M | 40.58M | 35.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 445.22M | 361.63M | 315.27M | 264.71M | 240.76M |
| Operating Income | -445.22M | -361.63M | -315.27M | -264.71M | -240.76M |
| Income Before Tax | -453.82M | -364.89M | -305.21M | -247.79M | -213.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -453.82M | -364.89M | -305.21M | -247.79M | -213.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -453.82M | -364.89M | -305.21M | -247.79M | -213.42M |
| EBIT | -445.22M | -361.63M | -315.27M | -264.71M | -240.76M |
| EBITDA | -442.88M | -359.39M | -313.24M | -262.89M | -239.10M |
| EPS Basic | -2.29 | -1.86 | -1.61 | -1.31 | -1.13 |
| Normalized Basic EPS | -1.43 | -1.16 | -1.01 | -0.82 | -0.71 |
| EPS Diluted | -2.29 | -1.86 | -1.61 | -1.31 | -1.13 |
| Normalized Diluted EPS | -1.43 | -1.16 | -1.01 | -0.82 | -0.71 |
| Average Basic Shares Outstanding | 198.10M | 196.67M | 189.23M | 188.58M | 188.15M |
| Average Diluted Shares Outstanding | 198.10M | 196.67M | 189.23M | 188.58M | 188.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |